- Home
- HCAI vs APM Comparison
HCAI vs APM Comparison
Compare HCAI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCAI | APM |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 7.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HCAI | APM |
|---|---|---|
| Price | $7.15 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.8M | 27.4K |
| Earning Date | 05-23-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.65 |
| 52 Week High | $10.60 | $4.47 |
Technical Indicators
Market Signals| Indicator | HCAI | APM |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 51.33 |
| Support Level | $0.41 | $0.77 |
| Resistance Level | $8.75 | $1.11 |
| Average True Range (ATR) | 1.10 | 0.07 |
| MACD | 0.44 | -0.00 |
| Stochastic Oscillator | 69.71 | 43.59 |
Price Performance
Historical ComparisonAbout HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.